Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM): A nationwide phase 2 trial of patients with smoldering and active multiple myeloma (MM)

Next Previous
Trial Profile

Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM): A nationwide phase 2 trial of patients with smoldering and active multiple myeloma (MM)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma; Smoldering multiple myeloma
  • Focus Therapeutic Use
  • Acronyms iStopMM

Most Recent Events

  • 13 Dec 2022 Results(n=1,814) evaluating if SARS-CoV-2 vaccination has an impact on the risk of progression from monoclonal gammopathy of undetermined significance to Multiple Myeloma or not, presented at the 64th American Society of Hematology Annual Meeting and Exposition
  • 14 Dec 2021 Results (n=189) assessing the feasibility of using CTPC analysis by next-generation flow cytometry (NGF) for disease monitoring in precursor conditions of MM and early detection of progression to active multiple myeloma, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
  • 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top